LABORATOIRES S.M.B. S.A. Successfully Concluded A Clinical Trial for Cholecalciferolseptembre 15, 2022
Laboratoires SMB’s cholecalciferol product is ideal in prevention of the seasonal bronchiolitis epidemicnovembre 11, 2022
An independent study has shown that Laboratoires SMB’s Axahaler has a superior delivered dose when compared to other devices. The Fine Particle Dose (FDP), the respirable dose critical to achieve treatment efficiency through inhalation treatment. There are 3 products in SMB’s portfolio : formoterol, fluticasone with enhanced bioavailability and its innovative ICS/LABA combination containing Budesonide and Salmeterol
This study confirms Laboratoires SMB ‘s expertise in Dry Powder inhalation, fruit of more than 20 years of research and development into such drug delivery systems.